Investors
Eastgate Biotech Corp., Engages Gunpowder Capital Corp.
April 25, 2017
Toronto, Ontario, April 25th, 2017 – Gunpowder Capital Corp., (CSE: GPC), (CSE: GPC.PR.A), (Frankfurt: YS6N), (“Gunpowder”, “GPC” or the “Corporation”) announced today that entered into various agreements with Eastgate Biotech Corp., (OTCPink: ETBI) (“Eastgate”).
Read moreEASTGATE BIOTECH’S RECENT ACQUISITION OMNI SURGERY + ANTI-AGING CENTRE APPOINTS DR. ISHAAN SUNDAR AS MEDICAL DIRECTOR
April 12, 2017
Dr. Ishaan Sundar has assumed the role of Medical Director effective immediately. Educated by the American Academy of Aesthetic Medicine, American Cosmetic Cellular Medicine Association, Laser Sheer Training Academy and trained in Injectable Placements, Dr. Sundar brings over 20 years of extensive practice to the OMNI state-of-the-art centre.
Read moreEASTGATE BIOTECH CORPORATION AND AC NOVA TECHNOLOGIES (ATI PHARMA) ANNOUNCE A JOINT VENTURE
April 7, 2017
PHARMACEUTICAL BIOTECH RESEARCH COMPANY EASTGATE BIOTECH CORPORATION AND AC NOVA TECHNOLOGIES (ATI PHARMA) ANNOUNCE A JOINT VENTURE TO COMMERCIALIZE EVIDENCE-BASED NATURAL THERAPIES FOCUSED ON GLUCOSE BALANCE AND CARDIOVASCULAR HEALTH
Read morePurchase and Sale Agreement to acquire Omni Surgery and Anti-Aging Centre
March 14, 2017
EastGate Biotech Corp.has entered into a Purchase and Sale Agreement to acquire OMNI Surgery and Anti-Aging Centre.
Read moreEASTGATE BIOTECH FEATURED ON UPTICK NEWSWIRE
July 11, 2016
WEST CALDWELL, NJ and TORONTO, July 11, 2016 (GlobeNewsire/-) EastGate Biotech Corp. (Pink Sheets: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has announced that CEO Anna Gluskin recently completed an interview with Mr. Everett Jolly from Uptick Newswire.
Read moreEASTGATE BIOTECH ANNOUNCES THAT IT HAS RECEIVED A SUBSTANTIAL ORDER FOR GLUCORA, ITS NATURAL GLUCOSE MANAGEMENT PRODUCT
May 2, 2016
We are pleased that we have received our first material order for Glucora” says Anna Gluskin, EastGate Biotech’s CEO. “We believe that Glucora is a product with mass market appeal and will play a key role in the company’s diabetes franchise.
Read moreEastgate Biotech CEO Anna Gluskin talks to ‘TheStockRadio.com’ about their products and delivery technology
February 8, 2016
We look forward to introducing the benefits of such delivery, that is now available through our nutraceutical products currently being sold on the market, to a larger audience” continues Gluskin.
Read moreEastGate Patent for Lorazopem
January 19, 2016
EASTGATE BIOTECH RECEIVES NOTICE OF PUBLICATION FROM THE US PATENT AND TRADEMARK OFFICE FOR TWO PATENTS FOR THE COMPANY’S PROPRIETARY INTRAORAL LORAZEPAM SPRAY
Read moreDo You Really Need An Antibiotic?
January 13, 2016
Shortly before I completed this column, I talked to a paraplegic patient who must use a catheter regularly to empty her bladder. This resulted in repeated infections in spite of five different antibiotics! She reported that use of UTI E-Drops resolved her dilemma.
Read more